137 related articles for article (PubMed ID: 20181162)
1. Interstitial pneumonitis associated with pegylated interferon-alpha 2a and ribavirin for chronic hepatitis C infection: a case report.
Atug O; Akin H; Alahdab YO; Ceyhan B; Tozun N; Ozdogan O
Cases J; 2009 Mar; 2():6464. PubMed ID: 20181162
[TBL] [Abstract][Full Text] [Related]
2. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Chen YC; Lu SN; Lin MC
Chang Gung Med J; 2007; 30(1):92-7. PubMed ID: 17477035
[TBL] [Abstract][Full Text] [Related]
3. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
[TBL] [Abstract][Full Text] [Related]
4. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
5. [Antiviral/immunomodulatory combination therapy: pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection].
Delić D; Mitrović N; Popović N; Urošević A; Pešiċ I; Simonoviċ J
Srp Arh Celok Lek; 2012; 140(9-10):612-8. PubMed ID: 23289278
[TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS.
Abi-Nassif S; Mark EJ; Fogel RB; Hallisey RK
Chest; 2003 Jul; 124(1):406-10. PubMed ID: 12853555
[TBL] [Abstract][Full Text] [Related]
7. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C.
Ishikawa T; Kubota T; Abe H; Hirose K; Nagashima A; Togashi T; Seki K; Honma T; Yoshida T; Kamimura T
Hepatogastroenterology; 2012 Oct; 59(119):2260-3. PubMed ID: 23435141
[TBL] [Abstract][Full Text] [Related]
8. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection.
Karim A; Ahmed S; Khan A; Steinberg H; Mattana J
Am J Med Sci; 2001 Oct; 322(4):233-5. PubMed ID: 11678522
[TBL] [Abstract][Full Text] [Related]
9. Erythema annulare centrifugum due to pegylated interferon-α-2a plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
Gönül M; Külcü Çakmak S; Ozcan N; Deniz Oǧuz I; Ozhamam E
J Cutan Med Surg; 2014; 18(1):65-8. PubMed ID: 24377478
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
Alsaran K; Sabry A; Shaheen N
Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
[TBL] [Abstract][Full Text] [Related]
11. The sustained virologic response of nonresponder hepatitis C virus patients with retreatment.
Akhan SC; Gurel E; Sayan M
Indian J Pathol Microbiol; 2011; 54(1):81-4. PubMed ID: 21393883
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
Kapol N; Lochid-Amnuay S; Teerawattananon Y
BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
Foster GR
Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous occurrence of pleural effusion and interstitial pneumonitis after treatment with pegylated interferon for hepatitis C virus infection.
Ji F; Li Z; Xue H; Liu L; Deng H
South Med J; 2011 Feb; 104(2):140-2. PubMed ID: 21206334
[TBL] [Abstract][Full Text] [Related]
15. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
16. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
[TBL] [Abstract][Full Text] [Related]
17. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
Baker RD; Dee D; Baker SS
J Clin Gastroenterol; 2007 Jan; 41(1):111-4. PubMed ID: 17198073
[TBL] [Abstract][Full Text] [Related]
18. Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report.
Carrillo-Esper R; González-Avila D; Uribe-Ríos M; Méndez-Sánchez N
Ann Hepatol; 2008; 7(1):87-90. PubMed ID: 18376374
[TBL] [Abstract][Full Text] [Related]
19. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.
Slavenburg S; Heijdra YF; Drenth JP
Dig Dis Sci; 2010 Mar; 55(3):579-85. PubMed ID: 19399621
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
Helal GK; Gad MA; Abd-Ellah MF; Eid MS
J Med Virol; 2016 Dec; 88(12):2170-2178. PubMed ID: 27183377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
